Compare ClearPoint Neuro Inc (CLPT) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Ferrari NV — how do they compare? ClearPoint Neuro Inc trades at $15.17 (market cap $454.21M), while Ferrari NV trades at $405.85 (market cap $71.67B). The key difference: Ferrari NV is far larger — about 157.8× ClearPoint Neuro Inc's market cap, and Ferrari NV pays a 1.04% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | RACE | |
|---|---|---|
Market Cap | $454.21M | $71.67B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.60 | $504.09 |
52-Week Low | $8.66 | $314.63 |
Enterprise Value | $488.79M | $73.60B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $15.20, up 4.32% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue growth but missed earnings estimates, with a net income margin of -81.76%. Recent news highlights regulatory progress with partners and expansion into focused ultrasound technology.
The outlook remains speculative with high growth potential in neurotherapy markets, but significant execution and profitability risks persist. Analyst consensus is unanimously bullish, though sustained losses and cash burn require careful monitoring for long-term investors.
Ferrari (RACE) trades at $405.73, down 0.26% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported Q2 2026 EPS of $2.99, beating estimates of $2.83, and raised full-year guidance, driven by robust personalization demand and pricing power. Revenue growth has been consistent, reaching $7.15B in 2025, with a net income margin of 22.25% and high profitability metrics like a 45.45% ROE.
The outlook remains positive given strong order books, margin expansion, and analyst consensus favoring a buy rating with a $462.67 price target. Key risks include premium valuation multiples limiting upside and sensitivity to luxury demand cycles. The stock's proximity to its 52-week high suggests momentum but warrants caution on overextension.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
